Isotachophoresis enhanced isothermal nucleic acid amplification

Patent metadata

Field	Value
Publication number	US-10227634-B2
Application number	US-201615566631-A
Country	US
Kind code	B2
Filing date	Apr 14, 2016
Priority date	Apr 15, 2015
Publication date	Mar 12, 2019
Grant date	Mar 12, 2019

Abstract

The present disclosure relates generally to the integration of isotachophoresis (ITP) and isothermal nucleic acid amplification methods such as recombinase polymerase amplification (RPA). One aspect of the disclosure relates to a method for concentrating and amplifying a nucleic acid, the method including an isotachophoresis device, the isotachophoresis device including a porous matrix, and first and second electrodes, having a leading electrolyte, a trailing electrolyte and a set of isothermal nucleic acid amplification reaction reagents disposed in the porous matrix as described herein, and applying a voltage across the first electrode and the second electrode for a time sufficient to provide a first isotachophoresis (ITP) plug comprising an amplification product of the nucleic acid, wherein the concentration of the nucleic acid is substantially higher in the first FTP plug than in the first and/or second fluids outside of the first ITP plug.

First claim

We claim:

1. A method for concentrating and amplifying a nucleic acid, the method comprising
providing an isotachophoresis device, the isotachophoresis device including
a porous matrix having a first end and a second end opposing the first end, the first end and the second end defining a first axis, the porous matrix having a first fluid pathway having a first end and extending to a second end,
a first electrode, and
a second electrode;
a first fluid comprising a trailing electrolyte, disposed in the porous matrix within the first fluid pathway, the trailing electrolyte comprising an ion and a counterion, the first fluid being disposed such that the first electrode is in conductive contact with the first end of the first fluid pathway,
a second fluid comprising a leading electrolyte, disposed in the porous matrix within the first fluid pathway, the leading electrolyte comprising an ion and a counterion, the ion of the trailing electrolyte having a lower effective electrophoretic mobility than the ion of the leading electrolyte,
a set of isothermal nucleic acid amplification (INAA) reaction reagents, disposed in the porous matrix within the first fluid pathway and
the nucleic acid disposed in the porous matrix within the first fluid pathway, the nucleic acid having a higher effective electrophoretic mobility than the ion of the trailing electrolyte and a lower effective electrophoretic mobility than the ion of the leading electrolyte; and

applying a voltage across the first electrode and the second electrode for a time sufficient to provide a first isotachophoresis (ITP) plug comprising an amplification product of the nucleic acid, wherein the concentration of the nucleic acid is substantially higher in the first ITP plug than in the first and/or second fluids outside of the first ITP plug.

2. The method according to claim 1 , wherein one or more reagents of the set of INAA reaction reagents are present in the second fluid, and/or wherein one or more of the reagents of the set of INAA reaction reagents are disposed within the porous matrix in the first fluid pathway before the first fluid and the second fluid are introduced to the first fluid pathway.

3. The method according to claim 1 , wherein providing the device comprises providing a dry device, the dry device comprising at least the porous matrix, the dry device further comprising one or more reagents of the set of INAA reaction reagents disposed in dry form in one or more zones of the first fluid pathway, the method comprising dissolving or suspending the one or more dry form INAA reaction reagents in the first fluid and/or the second fluid; or
providing a dry device, the dry device comprising at least the porous matrix, the dry device further comprising the leading electrolyte disposed in dry form in one or more zones of the first fluid pathway, the method comprising dissolving the leading electrolyte to form the second fluid; or
providing a dry device, the dry device comprising at least the porous matrix, the dry device further comprising the trailing electrolyte disposed in dry form in one or more zones of the first fluid pathway, the method comprising dissolving the trailing electrolyte to form the first fluid.

4. The method according to claim 1 , wherein the leading electrolyte is disposed closer to the second end of the first fluid pathway than is the trailing electrolyte.

5. The method according to claim 1 , wherein the nucleic acid is present in the first fluid.

6. The method according to claim 1 , wherein the second fluid is introduced to the first fluid pathway before the first fluid is introduced to the first fluid pathway, and/or wherein the first fluid is introduced to the first fluid pathway by disposing an end of the device into a body of the first fluid, such that the first fluid is absorbed into the first fluid pathway at the first end thereof.

7. The method according to claim 1 , wherein the second fluid is introduced to the first fluid pathway by disposing an end of the device into a body of the second fluid, such that the second fluid is absorbed into the first fluid pathway at the second end thereof, or wherein the second fluid is introduced to the first fluid pathway by dispensing the second fluid onto the first fluid pathway along the first axis.

8. The method according to claim 1 , wherein the concentration of the trailing electrolyte in the first fluid is between about 1 μM-500 mM, and/or wherein the concentration of the leading electrolyte in the second fluid is between about 1 mM-1 M.

9. The method according to claim 1 , wherein the effective mobility of the ion of the leading electrolyte is greater than about 4.0×10 −8 m 2 V −1 s −1 , and/or wherein the effective mobility of the ion of the trailing electrolyte is less than about 4.0×10 −8 m 2 V −1 s −1 and/or wherein the difference between the effective mobilities of the ion of the leading electrolyte and the ion of the trailing electrolyte is at least about 3×10 −8 m 2 V −1 s −1 .

10. The method according to claim 1 , wherein one or more of the reagents of the set of INAA reagents have an effective mobility between the effective mobility of the ion of the leading electrolyte and the ion of the trailing electrolyte; and/or wherein the one or more INAA reagents are recombinase polymerase amplification (RPA) reagents, and/or wherein the one or more INAA reagents are loop-mediated isothermal amplification (LAMP) reagents, helicase dependent amplifier reaction HDA), nicking enzyme amplification reaction (NEAR) reagents, nucleic acid sequence based amplification (NASBA) reagents, strand displacement amplification (SDA) reagents, or cross-priming amplification (CPA) reagents.

11. The method according to claim 1 , wherein the porous matrix has an average pore size in the range of about 0.1 μm to about 100 μm, and/or wherein the porous matrix has a porosity of at least 80%, and/or wherein the porous matrix has an internal surface area ratio in the range of about 50 to about 200, and/or wherein the porous matrix is formed from a glass, plastic, paper, polymer, or membrane material, and/or wherein the porous matrix is disposed in a closeable casing.

12. The method according to claim 1 , wherein the voltage applied to the provided device is between 1-2500 Volts, and/or wherein applying the voltage provides a current flow between 10 −6 -50 milliamperes to the provided device, and/or wherein applying the voltage provides a current flow sufficient to provide Joule heating of the first fluid pathway to a temperature of at least 25° C.

13. The method according to claim 1 , wherein the leading electrolyte comprises a chloride ion, a bicarbonate ion, a sulfate ion, an acetate ion, a bromide ion, a bromate ion, a chlorate ion, an iodate ion, a tris counterion, an imidazole counterion, a bis-tris counterion, a bis-tris propane counterion, or an ammediol counterion, or a nitrate ion, and/or wherein the trailing electrolyte comprises a HEPES ion, a glycine ion, a serine ion, a tricine ion, a bicine ion, a TAPS ion, a MOPS ion, a tris counterion, an imidazole counterion, a bis-tris counterion, a bis-tris propane counterion, or an ammediol counterion, a beta-alanine ion, a valine ion, a leucine ion, or an isoleucine ion.

14. The method according to claim 1 , wherein the first and/or second fluid further comprise at least one water-soluble material selected from the group comprising polymeric surfactants, charged polymers, polyol compounds, poly(vinyl alcohol), poly(alkylene glycol) polymers, polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), TWEEN® 20, TRITON™ X, polylactams, substituted polyacrylamide derivatives, and water

Assignees

• Univ Washington

Inventors

• Posner Jonathan D
• Borysiak Mark D
• Kimura Kevin

Classifications

• C12Q1/70

  involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)} · CPC title

• C12Q1/6806 Primary

  Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence) · CPC title

• C12Q2531/143

  Promoter based amplification, e.g. NASBA, 3SR, TAS · CPC title

• G01N27/44795 Primary

  Isoelectric focusing · CPC title

• C12Q2531/119

  Strand displacement amplification [SDA] · CPC title